ClinicalTrials.gg

Program

imzokitug

Also written as “Imzokitug” and “BMS-986340”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Uterine Cervical Neoplasms, led by Bristol-Myers Squibb.

Furthest: phase 2, since May 19, 20212 company-led studies, 2 open or runningNext primary completion: Sep 15, 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bristol-Myers Squibb22 open or runningphase 2since May 19, 2021May 19, 2021Sep 15, 2028phase 2 · NCT07680764
  • Named in Bristol-Myers Squibb’s own pipeline as imzokitug, phase 2, as of Oct 29, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 19, 2021First study: phase 2 study in Uterine Cervical NeoplasmsFirst studyNCT04895709 · 1,109 planned · United States, Australia, Canada and more
  2. Jun 26, 2026Phase 2 study in Carcinoma, Non-Small-Cell LungNCT07680764 · 160 planned · United States, Argentina, Australia and more

Ahead

  1. Sep 15, 2028Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungNCT07680764
  2. Aug 31, 2031Primary completion: phase 2 study in Uterine Cervical NeoplasmsNCT04895709

TargetBeta

“A human immunoglobulin G1 (IgG1) nonfucosylated (NF) monoclonal antibody against C-C-chemokine receptor 8 (CCR8), with potential immunomodulating and antineoplastic activities. Upon administration, imzokitug targets, binds to and blocks the activity of CCR8 on CCR8-positive tumor-infiltrating reg…”NCIt, read by Claude
“A human immunoglobulin G1 (IgG1) nonfucosylated (NF) monoclonal antibody against C-C-chemokine receptor 8 (CCR8), ”NCIt, by rule

Other programs on CCR8

ProgramCompanyFurthest phaseStudies
cafelkibartSino Biopharmaceuticalphase 37
CCR8 Inhibitor IPG7236rulenanjing-immunophage-biotech-co-ltdphase 23
denikitugruleGilead Sciencesphase 23
Anti-CCR8 Antibody-drug Conjugate TAK-188ruleTakedaphase 21
Anti-CCR8 Monoclonal Antibody HC006rulehc-biopharma-incphase 12
azirkitugAbbViephase 11

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07680764Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more2RecruitingSep 15, 2028160
NCT04895709Uterine Cervical Neoplasms · United States, Australia, Canada and more2RecruitingAug 31, 20311,109

How it is read

Names in the registry

  • “Imzokitug”, 1 entry
  • “BMS-986340”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.